Goldman Sachs analyst Rajan Sharma maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £16.80.

In the vaccines segment, GSK maintained its leadership in the self-pay private market for Paediatric vaccines, the company ...

NEW YORK CITY, NY / ACCESS Newswire / February 19, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies ...

GlaxoSmithKline Pharmaceuticals shares surged 20% to ₹2,421.30 after a strong Q3FY25 performance, reporting a 400% rise in ...

GSK PLC closed 20.87% below its 52-week high of £18.24, which the company reached on May 16th.

DelveInsight's Transmucosal Drugs Market Insights report provides the current and forecast market analysis, individual ...

Penmenvy, which protects against five common types of disease-causing bacteria, is cleared for use in people aged 10 through ...

Citadel has taken a short position worth 305 million pounds ($384.5 million) in GSK stock, representing a 0.51% stake, ...

Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has bee ...

The increasing prevalence of chronic conditions like cardiovascular disease is driving the demand for transmucosal drugs. Key factors contributing to the transmucosal drugs market's growth from ...

The U.S. Food and Drug Administration (FDA) approved GSK's combination vaccine to protect against meningococcal infection for ...